Clinical Trials for Prostate Cancer Recruiting Now: SBRT + Relugolix (SUGAR Study) in New Haven, New York and Seattle

Prostate cancer remains one of the most common cancers diagnosed in men in the United States. For patients with intermediate-risk disease, treatment decisions often involve balancing cancer control with quality-of-life impacts from therapies like radiation and hormone suppression.

Clinical trials are testing optimized approaches. One actively recruiting Phase 2 study is evaluating stereotactic body radiotherapy (SBRT) alone versus SBRT combined with the oral medication Relugolix for a specific subgroup of patients.

Actively Recruiting Trial: The SUGAR Study (NCT06111781)

NCT ID: NCT06111781
Sponsor: Yale University
Phase: 2
Status: RECRUITING
Key Locations (United States):

• New Haven, Connecticut (Yale Cancer Center)
• New York, New York (Memorial Sloan Kettering Cancer Center)
• Seattle, Washington (University of Washington)

Study Design Highlights:

• Randomized assignment to SBRT alone or SBRT + Relugolix (ultrashort GNRH antagonist / oral ADT).
• Focus on clinicogenomic unfavorable intermediate risk (cFIR/cgUIR) prostate cancer: favorable clinical features (Gleason 3+4 with PSA <20 or Gleason 6 with PSA 10-20) but high genomic risk (Decipher GC score ≥0.6).
• Primary goals: higher rate of PSA nadir ≤0.2 ng/mL with the combination; superior maintenance of sexual and hormonal function (minimal clinically important decline) at 6 months compared to historical 6-month ADT rates.
• Duration and follow-up aligned with standard SBRT timelines plus short-course Relugolix overlapping radiation.
• Men aged 18+, histologically confirmed prostate adenocarcinoma, serum testosterone >100 ng/dL, prostate volume ≤80 cc, willing to use effective contraception.

Key Eligibility Criteria (summary):

• Confirmed adenocarcinoma of the prostate.
• Clinical favorable intermediate risk with high genomic risk per Decipher score.
• No prior prostate-directed surgery or radiotherapy.
• Able to swallow oral medication.

Exclusions include: Current QT-prolonging meds, known allergy to relugolix, inflammatory bowel disease history, connective tissue disease, long QT syndrome, surgical castration, or recent investigational treatment.

This trial aims to determine if adding short-course Relugolix to SBRT improves cancer control metrics while reducing the side-effect burden of longer traditional androgen deprivation therapy.

Standard Treatments vs. Investigational Approaches in Prostate Cancer Trials

Approach	Examples	Typical Use Case	Limitations
Standard EBRT / SBRT alone	External beam or stereotactic body radiotherapy	Localized intermediate-risk prostate cancer	May benefit from added systemic therapy in higher genomic risk cases
ADT (androgen deprivation therapy)	6+ months GNRH agonists/antagonists + radiation	Intermediate to high-risk disease	Side effects: hot flashes, fatigue, sexual dysfunction, bone/heart risks
Investigational (SUGAR: SBRT + ultrashort Relugolix)	Oral Relugolix overlapping SBRT only	Clinicogenomic unfavorable intermediate risk	Early phase data; long-term outcomes and optimal duration still under study
Other trials	Novel agents, biomarker-driven de-escalation	Various risk groups	Vary by eligibility; not all patients qualify

Note: This is for informational purposes only. Eligibility and outcomes are determined by the study team.

How Corterve Helps Patients Find Prostate Cancer Trials

Corterve's platform matches patients to recruiting clinical trials using:

• Condition-specific search (e.g., "prostate cancer" or "intermediate risk prostate cancer").
• Location and travel radius filtering (New Haven, NYC, Seattle areas and beyond).
• Structured pre-screening based on stage, Gleason score, PSA, genomic tests like Decipher, and prior treatments.
• Direct referral to study sites when you pre-qualify.

Search actively recruiting prostate cancer trials: Corterve Prostate Cancer Trials

Get personalized alerts: Register with your ZIP code to be notified of new studies near you.

Questions to Ask Your Urologist or Radiation Oncologist

• Does my genomic profile (e.g., Decipher score) suggest I might benefit from short-course ADT with SBRT?
• Am I a candidate for the SUGAR study or similar trials combining SBRT with Relugolix or other agents?
• What are the expected side effects of Relugolix compared to longer ADT courses?
• How does SBRT compare to standard fractionation in terms of convenience and long-term control for my case?
• What follow-up monitoring (PSA, imaging, quality-of-life assessments) is involved?
• Are there other open prostate cancer trials (e.g., de-escalation, new oral agents, or focal therapies) that might fit better?

Important: Pre-qualification on Corterve is a first step only. The research site's team makes the final eligibility determination after full medical review, including exams, labs, and imaging. Prostate cancer treatment decisions should always be made with your multidisciplinary care team (urologist, radiation oncologist, medical oncologist).

Disclaimer: Corterve is a clinical trial matching platform, not a medical provider. We do not give medical advice, diagnose conditions, or guarantee trial eligibility or outcomes. All eligibility determinations and medical decisions are made by the study's research team and your healthcare providers. This post uses publicly available trial metadata for informational purposes only. Consult a qualified healthcare professional before considering any clinical trial or changing your treatment plan.